P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

Exclusion Criteria

• •Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions at (eg, eczema) that would interfere with study evaluations
• •Subject has known history of Crohn's disease
• •Subject has any other significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol
• •Subject has not stopped using certain psoriasis therapies as defined in the study protocol
• •Subject has previously used ustekinumab or any anti-IL-17 biologic therapy
• •Subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in the study
• •Female subject is unwilling to use highly effective methods of birth control unless 2 years post-menopausal or surgically sterile